Clinical outcomes of an integrated primary-secondary model of care for individuals with complex type 2 diabetes: a non-inferiority randomised controlled trial.


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
01 2019
Historique:
received: 17 04 2018
accepted: 05 09 2018
pubmed: 5 10 2018
medline: 6 6 2019
entrez: 5 10 2018
Statut: ppublish

Résumé

The aim of the study was to determine if a Beacon model of integrated care utilising general practitioners (GPs) with special interests could achieve similar clinical outcomes to a hospital-based specialist diabetes outpatient clinic. This pragmatic non-inferiority multisite randomised controlled trial assigned individuals with complex type 2 diabetes to care delivered by a Beacon clinic or to usual care delivered by a hospital outpatient department, in a 3:1 ratio. Owing to the nature of the study, researchers were only blinded during the allocation process. Eligible participants were aged 18 or over, had been referred by their usual GP to the hospital central referral hub with type 2 diabetes and had been triaged to be seen within 30 or 90 days. The intervention consisted of diabetes management in primary care by GPs with a special interest who had been upskilled in complex diabetes under the supervision of an endocrinologist. The primary outcome was HbA Between 27 November 2012 and 14 July 2015, 352 individuals were recruited and 305 comprised the intention-to-treat sample (71 in usual care group and 234 in the Beacon model group). The Beacon model was non-inferior to usual care for both the per-protocol (difference -0.38 mmol/mol [95% CI -4.72, 3.96]; -0.03% [95% CI -0.43, 0.36]) and the intention-to-treat (difference -1.28 mmol/mol [95% CI -5.96, 3.40]; -0.12% [95% CI -0.55, 0.31]) analyses. Non-inferiority was sustained in a sensitivity analysis at 12 months. There were no statistically or clinically significant differences in the secondary outcomes of BP, lipids or quality of life as measured by the 12 item short-form health survey (SF-12v2) and the diabetes-related quality of life (DQoL-Brief) survey. Safety indicators did not differ between groups. Participant satisfaction on the eight-item client satisfaction questionnaire (CSQ-8) was good in both groups, but scores were significantly higher in the Beacon model group than the usual care group (mean [SD] 28.4 [4.9] vs 25.6 [4.9], respectively, p < 0.001). In individuals with type 2 diabetes, a model of integrated care delivered in the community by GPs with a special interest can safely achieve clinical outcomes that are not inferior to those achieved with gold-standard hospital-based specialist outpatient clinics. Individuals receiving care in the community had greater satisfaction. Further studies will determine the cost of delivering this model of care. Australian New Zealand Clinical Trials Registry ACTRN12612000380897 FUNDING: The study was funded by the Australian National Health and Medical Research Council (GNT1001157).

Identifiants

pubmed: 30284015
doi: 10.1007/s00125-018-4740-x
pii: 10.1007/s00125-018-4740-x
doi:

Substances chimiques

Glycated Hemoglobin A 0

Banques de données

ANZCTR
['ACTRN12612000380897']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

41-52

Références

Fam Pract. 2004 Feb;21(1):39-45
pubmed: 14760042
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Health Soc Care Community. 2017 May;25(3):1031-1040
pubmed: 27782342
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Aust Health Rev. 2018 Jun;42(3):299-302
pubmed: 28483036
Int J Qual Health Care. 2005 Apr;17(2):141-6
pubmed: 15665066
Diabet Med. 2016 Jun;33(6):768-76
pubmed: 27194175
Trials. 2011 May 03;12:106
pubmed: 21539749
Cochrane Database Syst Rev. 2017 Feb 23;2:CD004910
pubmed: 28230899
N Engl J Med. 2008 Feb 7;358(6):580-91
pubmed: 18256393
Rural Remote Health. 2012 Oct;12(4):2265
pubmed: 23198702
Diabetes Res Clin Pract. 2014 Feb;103(2):137-49
pubmed: 24630390
Diabet Med. 2004 Jan;21(1):32-8
pubmed: 14706051
Aust Fam Physician. 2010 Dec;39(12):972-4
pubmed: 21301683
JAMA. 2017 Aug 15;318(7):637-646
pubmed: 28810024
BMJ. 2015 Apr 21;350:h2005
pubmed: 25899794
J Health Serv Res Policy. 2017 Jan;22(1):53-64
pubmed: 27165979
J Gen Intern Med. 2009 Aug;24(8):939-45
pubmed: 19506971
Int J Integr Care. 2001;1:e21
pubmed: 16896400
Diabetes Obes Metab. 2012 Mar;14(3):228-33
pubmed: 21958121
Aust J Prim Health. 2013;19(3):207-12
pubmed: 22951067
Int J Qual Health Care. 2014 Oct;26(5):561-70
pubmed: 25108537
BMJ. 2005 Dec 17;331(7530):1441-6
pubmed: 16332728
Diabetes Care. 2017 Sep;40(9):1273-1284
pubmed: 28830958
Trials. 2013 Nov 12;14:382
pubmed: 24220342
Diabetes Res Clin Pract. 2010 Apr;88(1):56-64
pubmed: 20047770
BMC Health Serv Res. 2010 Nov 04;10:303
pubmed: 21050488
Diabet Med. 2013 Sep;30(9):1112-21
pubmed: 23758279
Br J Gen Pract. 2001 Apr;51(465):264-9
pubmed: 11458477

Auteurs

Anthony W Russell (AW)

Faculty of Medicine, The University of Queensland, Level 8, Health Sciences Building, Royal Brisbane and Women's Hospital, Herston, QLD, 4006, Australia. Anthony.Russell2@health.qld.gov.au.
Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, QLD, Australia. Anthony.Russell2@health.qld.gov.au.

Maria Donald (M)

Faculty of Medicine, The University of Queensland, Level 8, Health Sciences Building, Royal Brisbane and Women's Hospital, Herston, QLD, 4006, Australia.

Samantha J Borg (SJ)

Faculty of Medicine, The University of Queensland, Level 8, Health Sciences Building, Royal Brisbane and Women's Hospital, Herston, QLD, 4006, Australia.

Jianzhen Zhang (J)

Faculty of Medicine, The University of Queensland, Level 8, Health Sciences Building, Royal Brisbane and Women's Hospital, Herston, QLD, 4006, Australia.

Letitia H Burridge (LH)

Faculty of Medicine, The University of Queensland, Level 8, Health Sciences Building, Royal Brisbane and Women's Hospital, Herston, QLD, 4006, Australia.

Robert S Ware (RS)

Menzies Health Institute Queensland, Griffith University, Brisbane, QLD, Australia.

Nelufa Begum (N)

Faculty of Medicine, The University of Queensland, Level 8, Health Sciences Building, Royal Brisbane and Women's Hospital, Herston, QLD, 4006, Australia.

H David McIntyre (HD)

Faculty of Medicine, The University of Queensland, Level 8, Health Sciences Building, Royal Brisbane and Women's Hospital, Herston, QLD, 4006, Australia.

Claire L Jackson (CL)

Faculty of Medicine, The University of Queensland, Level 8, Health Sciences Building, Royal Brisbane and Women's Hospital, Herston, QLD, 4006, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH